OMIC vs. CARA, AKYA, BNGO, PRE, RPID, AXDX, TLIS, ASTC, HLTH, and PRPO
Should you be buying Singular Genomics Systems stock or one of its competitors? The main competitors of Singular Genomics Systems include Cara Therapeutics (CARA), Akoya Biosciences (AKYA), Bionano Genomics (BNGO), Prenetics Global (PRE), Rapid Micro Biosystems (RPID), Accelerate Diagnostics (AXDX), Talis Biomedical (TLIS), Astrotech (ASTC), Cue Health (HLTH), and Precipio (PRPO).
Cara Therapeutics (NASDAQ:CARA) and Singular Genomics Systems (NASDAQ:OMIC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability.
Cara Therapeutics has a net margin of -723.49% compared to Cara Therapeutics' net margin of -3,863.90%. Cara Therapeutics' return on equity of -51.10% beat Singular Genomics Systems' return on equity.
44.7% of Cara Therapeutics shares are held by institutional investors. Comparatively, 65.8% of Singular Genomics Systems shares are held by institutional investors. 3.1% of Cara Therapeutics shares are held by insiders. Comparatively, 22.2% of Singular Genomics Systems shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Singular Genomics Systems has lower revenue, but higher earnings than Cara Therapeutics. Cara Therapeutics is trading at a lower price-to-earnings ratio than Singular Genomics Systems, indicating that it is currently the more affordable of the two stocks.
Cara Therapeutics has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500. Comparatively, Singular Genomics Systems has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500.
Cara Therapeutics presently has a consensus price target of $11.12, suggesting a potential upside of 1,612.35%. Singular Genomics Systems has a consensus price target of $0.63, suggesting a potential upside of 71.37%. Given Singular Genomics Systems' stronger consensus rating and higher probable upside, analysts plainly believe Cara Therapeutics is more favorable than Singular Genomics Systems.
In the previous week, Cara Therapeutics had 3 more articles in the media than Singular Genomics Systems. MarketBeat recorded 6 mentions for Cara Therapeutics and 3 mentions for Singular Genomics Systems. Cara Therapeutics' average media sentiment score of 0.96 beat Singular Genomics Systems' score of 0.73 indicating that Singular Genomics Systems is being referred to more favorably in the news media.
Cara Therapeutics received 654 more outperform votes than Singular Genomics Systems when rated by MarketBeat users. Likewise, 75.03% of users gave Cara Therapeutics an outperform vote while only 46.43% of users gave Singular Genomics Systems an outperform vote.
Summary
Singular Genomics Systems beats Cara Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Singular Genomics Systems News Delivered to You Automatically
Sign up to receive the latest news and ratings for OMIC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OMIC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Singular Genomics Systems Competitors List
Related Companies and Tools
